Skip to Main Content
Contribute Try STAT+ Today

A medical watchdog group is calling on the National Institutes of Health to immediately stop the enrollment of patients in a clinical trial of sepsis treatment and launch an investigation of how the study received approval, arguing that it puts patients at risk of serious harm, including death.

The group, Public Citizen, says in a letter dated Tuesday that the study’s protocol is also so “fundamentally flawed” that it will not produce reliable findings.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • this trial will not be helpful its plainly intuitive to an intensivist treating a septic pt fluids and if they dont work pressors – the goal is to maintain a MAP >65 and individulailize tx – ie back off fluid if your pt has CHf or CMO so as to not put them in pulm edema. No trial will authoritatively be able to say which path is better.

Comments are closed.